MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
T2 Biosystems General and Administrative Expenses 2011-2026 | TTOO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.8 M | 30.6 M | 28.5 M | 21.3 M | 27.3 M | 25.7 M | 22.8 M | 24.1 M | 19.1 M | 11 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.6 M | 11 M | 23.5 M |
Quarterly General and Administrative Expenses T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.38 M | 5.47 M | 6.74 M | - | 5.98 M | 6.3 M | 7.3 M | - | 7.02 M | 7.82 M | 9.23 M | - | 8.54 M | 7.24 M | 6.2 M | - | 5.27 M | 5.3 M | 6.66 M | 7.55 M | 5.98 M | 6.72 M | 7.06 M | 6.46 M | 5.87 M | 7.61 M | 5.76 M | 5.56 M | 5.56 M | 5.76 M | 5.87 M | 5.8 M | 5.94 M | 6.14 M | 6.2 M | 5.01 M | 5.18 M | 4.44 M | 4.47 M | 3.75 M | 2.98 M | 2.45 M | 1.84 M | - | 1.28 M | 1.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.23 M | 1.28 M | 5.68 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
1.62 B | $ 116.83 | 2.6 % | $ 35.5 B | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 25.13 | 1.19 % | $ 698 M | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | USA |
 |
Danaher Corporation
DHR
|
8.24 B | $ 196.66 | 2.95 % | $ 140 B | USA |
 |
CareDx, Inc
CDNA
|
108 M | $ 18.02 | 1.98 % | $ 960 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
1.29 B | $ 65.77 | 4.21 % | $ 25.7 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 16.25 | 2.14 % | $ 491 M | USA |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 15.84 | -1.55 % | $ 170 M |  China |
 |
Guardant Health
GH
|
211 M | $ 94.49 | 1.28 % | $ 11.8 B | USA |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
743 M | $ 176.18 | 3.87 % | $ 8.73 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
80.5 M | $ 14.28 | -1.72 % | $ 1.85 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 108.06 | 0.84 % | $ 8.91 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
9.48 M | $ 1.99 | -0.25 % | $ 8.8 M | USA |
 |
OpGen
OPGN
|
4.54 M | - | -16.95 % | $ 1.54 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 128.36 | 1.52 % | $ 20.4 B | USA |
 |
PerkinElmer
PKI
|
992 M | - | -0.91 % | $ 14.7 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 174.45 | 2.3 % | $ 30 B | USA |
 |
Quotient Limited
QTNT
|
37.4 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 275.15 | 2.22 % | $ 22.9 B | USA |
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.66 | -1.3 % | $ 86.3 K | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 80.09 | 2.57 % | $ 5.41 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.16 | - | $ 4.96 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.17 | 0.02 % | $ 6.37 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | Israel |
 |
Medpace Holdings
MEDP
|
198 M | $ 523.59 | 2.96 % | $ 15.1 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 323.64 | 4.22 % | $ 27.3 B | Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.86 | 2.43 % | $ 450 M | USA |
 |
Celcuity
CELC
|
27.2 M | $ 116.44 | 0.76 % | $ 5.44 B | USA |
 |
NeoGenomics
NEO
|
273 M | $ 8.3 | 2.98 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
218 M | $ 10.53 | 5.46 % | $ 2.28 B | USA |
 |
Natera
NTRA
|
589 M | $ 211.61 | 1.12 % | $ 20.8 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.63 | 3.43 % | $ 395 M | USA |